Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Paul F Pollack

Showing results (1-10 of 20) with videos related to

Pageof 2
Sort By:
The American Journal of Gastroenterology|November 8, 2011
When meta-analysis misleadsMei Yang, Anne M Robinson, Paul F Pollack
Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research|May 21, 2008
Loss of treatment response to infliximab maintenance therapy in Crohn's disease: a payor perspectiveEric Qiong Wu, Parvez M Mulani, Andrew Peng Yu, et al.
Inflammatory Bowel Diseases|February 26, 2011
Adalimumab produces clinical remission and reduces extraintestinal manifestations in Crohn's disease: results from CARERobert Löfberg, Edouard V Louis, Walter Reinisch, et al.
Inflammatory Bowel Diseases|May 14, 2013
52-week efficacy of adalimumab in patients with moderately to severely active ulcerative colitis who failed corticosteroids and/or immunosuppressantsWalter Reinisch, William J Sandborn, Remo Panaccione, et al.
Inflammatory Bowel Diseases|September 3, 2011
Effect of adalimumab on clinical laboratory parameters in patients with Crohn's disease: results from the CHARM trialDavid T Rubin, Parvez Mulani, Jingdong Chao, et al.
Journal of Crohn'S & Colitis|April 7, 2012
Adalimumab improves patient-reported outcomes and reduces indirect costs in patients with moderate to severe Crohn's disease: results from the CARE trialEdouard Louis, Robert Löfberg, Walter Reinisch, et al.
Pancreas|October 27, 2015
Efficacy and Safety of Pancrelipase/Pancreatin in Patients With Exocrine Pancreatic Insufficiency and a Medical History of Diabetes MellitusDavid C Whitcomb, Amit Bodhani, Katrin Beckmann, et al.
Inflammatory Bowel Diseases|September 18, 2010
Dosage adjustment during long-term adalimumab treatment for Crohn's disease: clinical efficacy and pharmacoeconomicsWilliam J Sandborn, Jean-Frédéric Colombel, Stefan Schreiber, et al.
Inflammatory Bowel Diseases|April 16, 2013
Serum adalimumab concentration and clinical remission in patients with Crohn's diseaseYi-Lin Chiu, David T Rubin, Severine Vermeire, et al.
Journal of Pediatric Gastroenterology and Nutrition|January 22, 2004
Safety and efficacy of a premixed, rice-based oral rehydration solutionIrene Maulen-Radovan, Pedro Gutierrez-Castrellón, Mohamed Hashem, et al.
Pageof 2

Showing results (1-10 of 20) with videos related to

Sort By:
Pageof 2
The American Journal of Gastroenterology|November 8, 2011
When meta-analysis misleadsMei Yang, Anne M Robinson, Paul F Pollack
Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research|May 21, 2008
Loss of treatment response to infliximab maintenance therapy in Crohn's disease: a payor perspectiveEric Qiong Wu, Parvez M Mulani, Andrew Peng Yu, et al.
Inflammatory Bowel Diseases|February 26, 2011
Adalimumab produces clinical remission and reduces extraintestinal manifestations in Crohn's disease: results from CARERobert Löfberg, Edouard V Louis, Walter Reinisch, et al.
Inflammatory Bowel Diseases|May 14, 2013
52-week efficacy of adalimumab in patients with moderately to severely active ulcerative colitis who failed corticosteroids and/or immunosuppressantsWalter Reinisch, William J Sandborn, Remo Panaccione, et al.
Inflammatory Bowel Diseases|September 3, 2011
Effect of adalimumab on clinical laboratory parameters in patients with Crohn's disease: results from the CHARM trialDavid T Rubin, Parvez Mulani, Jingdong Chao, et al.
Journal of Crohn'S & Colitis|April 7, 2012
Adalimumab improves patient-reported outcomes and reduces indirect costs in patients with moderate to severe Crohn's disease: results from the CARE trialEdouard Louis, Robert Löfberg, Walter Reinisch, et al.
Pancreas|October 27, 2015
Efficacy and Safety of Pancrelipase/Pancreatin in Patients With Exocrine Pancreatic Insufficiency and a Medical History of Diabetes MellitusDavid C Whitcomb, Amit Bodhani, Katrin Beckmann, et al.
Inflammatory Bowel Diseases|September 18, 2010
Dosage adjustment during long-term adalimumab treatment for Crohn's disease: clinical efficacy and pharmacoeconomicsWilliam J Sandborn, Jean-Frédéric Colombel, Stefan Schreiber, et al.
Inflammatory Bowel Diseases|April 16, 2013
Serum adalimumab concentration and clinical remission in patients with Crohn's diseaseYi-Lin Chiu, David T Rubin, Severine Vermeire, et al.
Journal of Pediatric Gastroenterology and Nutrition|January 22, 2004
Safety and efficacy of a premixed, rice-based oral rehydration solutionIrene Maulen-Radovan, Pedro Gutierrez-Castrellón, Mohamed Hashem, et al.
Pageof 2